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Carcinomas of unknown primary (CUP) represent between 3 and 10% of malignancies. Treatment with nonspecific chemotherapy is
commonly unhelpful and the median survival is between 3 and 6 months. Gene expression microarray (GEM) analysis has
demonstrated that molecular signatures can aid in tumour classification and propose foster primaries. In this study, we demonstrate
the clinical utility of a diagnostic gene expression profiling tool and discuss its potential implications for patient management strategies.
Paraffin tumour samples from 21 cases of ‘true’ CUP patients in whom standard investigation had failed to determine a primary site of
malignancy were investigated using diagnostic gene profiling. The results were reviewed in the context of histology and clinical history.
Classification of tumour origin using the GEM method confirmed the clinicians’ suspicion in 16 out of 21 cases. There was a clinical/
GEM inconsistency in 4 out of 21 patients and a pathological/GEM inconsistency in 1 patient. The improved diagnoses by the GEM
method would have influenced the management in 12 out of 21 cases. Genomic profiling and cancer classification tools represent a
promising analytical approach to assist with the management of CUP patients. We propose that GEM diagnosis be considered when
the primary clinical algorithm has failed to provide a diagnosis.
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Patients with carcinoma of unknown primary (CUP) present with
metastatic disease for which the primary site cannot be found
despite standard investigation. The incidence of patients with CUP
is estimated at 3–10% and despite recent improvements in
diagnosis there remains a cohort of ‘true’ CUP patients. Most
clinical algorithms rely on clinical investigation and immunohisto-
chemistry (IHC) with a growing panel of antibodies of different
tumour specificity (Hainsworth et al, 1991; Raber et al, 1992;
Brown et al, 1997; DeYoung and Wick, 2000; Varadhachary et al,
2004). Persistent investigation outside of algorithms rarely leads to
the detection of a primary site as well as being emotionally,
physically and financially draining. Where algorithms fail,
physicians should avoid the temptation to ‘guess’.
Patients with CUP constitute not only those elderly with poor
performance status (PS) and multiple comorbidities but also those
who respond to treatment, resulting in both improved quality of
life and survival. Multiple empirical chemotherapy regimens have
been used for CUP patients, but there are few randomised data to
support a specific regimen (Briasoulis et al, 2005). The median
survival in randomised studies is approximately 7 months
(Abbruzzese et al, 1995), which is both poor and significantly less
than the expected survival for patients with breast and bowel
malignancy following standard therapy. These data suggest that
little further benefit can be gained from the use of empirical
regimen, perhaps because of the heterogeneity of tumour
phenotype represented in the true CUP population. It follows that
specific treatment programmes may be beneficial in specific
patients if the diagnosis can be improved.
Recently, several independent studies have demonstrated proof of
principle for the use of gene expression microarrays (GEMs) in
identifying a foster primary site for CUP (Giordano et al, 2001;
Ramaswamy et al,2 0 0 1 ;S uet al,2 0 0 1 ;D e n n i set al, 2002;
Buckhaults et al, 2003; Shedden et al, 2003; Bloom et al, 2004; Tothill
et al, 2005) Data from GEM of known primary tumours have been
examined ‘blindly’ and the correct primary site identified with up to
89% accuracy. The success of these studies demonstrates that
patterns of gene expression remain consistent with tissue of origin,
both in cell lines (Ross et al, 2000) and tumour samples (Khan et al,
2001). Tothill and co-workers have developed a data set using 229
cancers and used this to predict a foster primary in a potential CUP
population. Predictions were made in 11 out of 13 cases analysed
but these patients were in the early stages of the diagnostic process
and the diagnosis may have been obtained without the help of
molecular prediction. Although this represents a validate of the
technique, these are not ‘true’ CUP patients.
The clinical application of using GEM analysis to direct patient
management has not been demonstrated in prospective studies. A
major hurdle has been the availability of fresh tumour tissue, as
the preservation of diagnostic material is nearly always in formalin
and paraffin. RNA isolation from these materials has been
challenging, but significant improvements in RNA isolation
protocols for archival formalin-fixed, paraffin-embedded (FFPE)
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stissues have been made in recent years. By exploiting these
advancements in RNA isolation methods, Ma et al (2006)
developed a microarray gene expression database of 466 frozen
and 112 FFPE samples of both primary and metastatic tumours,
representing 43 tumour types. Using this database, a k-nearest
neighbour classifier was constructed, which was subsequently
transformed into a high-throughput diagnostic CUP microarray
test.
In this study, we describe the use of this diagnostic classifier to
examine tumours of 21 CUP patients and compare the results with
results from clinical and histological information. We describe the
process, the clinical relevance of each result and the implications
for patient management. We propose a strategy to advance the
approach of tumour-specific management for patients with CUP.
MATERIALS AND METHODS
Study design
This was a retrospective analysis of 21 patients with CUP
diagnosed between September 2000 and May 2006. Patients were
diagnosed and treated at three centres in the North London Cancer
Network and the laboratory analysis performed at a single centre
(Agendia BV, Amsterdam, The Netherlands). Ethical approval was
obtained for the study. As internal controls, three samples from
one patient taken at different times and two samples from another
patient taken from two different anatomical sites were tested.
Patients
Eligible patients were those who had undergone standard
investigation for CUP. Histologically or cytologically confirmed
adenocarcinoma, poorly differentiated carcinoma and squamous
cell carcinoma were permitted. There had been no primary site
identified following complete history, physical examination,
chemistry profile, computed tomography (CT) scan of the chest,
abdomen, and pelvis, mammography in women, PSA in men and
directed workup of any symptomatic areas. Patients in the
following categories were excluded: women with adenocarcinoma
involving only axillary lymph nodes or the peritoneal cavity,
patients with squamous cell carcinoma involving only cervical
lymph nodes or inguinal lymph nodes, patients with poorly
differentiated carcinoma consistent with a germ cell tumour
(isolated midline structures, multiple pulmonary nodules, or
elevated levels of b-human chorionic gonadotropin or a-fetopro-
tein), men with prostate-specific antigen elevated in their plasma
or stained in their tumour, patients with a single, small, potentially
resectable tumour and patients with neuroendocrine carcinomas.
Laboratory analysis
Three 4-mm paraffin sections per patient were submitted for RNA
isolation and microarray analysis. One section from each tumour
sample was stained with haematoxylin and eosin for histological
evaluation, and RNA was isolated, amplified and labelled, as
described previously (Ma et al, 2006). Purified amplified cRNA was
then conjugated to Cy-mono NHS ester (GE Healthcare, Little
Chalfont Bucks, UK). Cy5 is used for the experimental samples and
Cy3 for the reference sample. The labelled cRNAs were subse-
quently hybridised to a customised eight-pack microarray (R van
Laar, personal communication). After hybridisation, the slides
were washed and subsequently scanned with a dual-laser scanner
(Agilent Technologies, Mountain View, CA, USA).
Data analysis
The diagnostic eight-pack array consists of eight mini arrays with
1900 features each, and these features comprise 255 positive
controls, 100 negative controls and 1545 biological sequences used
for data normalisation and sample classification. Selection and
validation of biological sequences used for sample classification is
described elsewhere (Ma et al, 2006). Fluorescence intensities,
captured in the form of TIFF images, were quantified, corrected for
nonspecific background hybridisation, and normalised using
Agilent Feature Extraction software (Version 8.5.1; Agilent
Technologies).
A five-nearest neighbour algorithm (Kuruvilla et al, 2002) is
used to determine the five most molecularly similar tumours in the
CupPrint database, which consists of a total of 643 samples
representing 48 tumour types. The class labels (i.e., tumour type)
of these ‘neighbouring’ samples are used to infer the tumour type
of each test sample. In the case of multiple tumour types being
present within the nearest five neighbours to a given test sample,
the ranking and number of each class within these five positions
are taken into consideration. The GEM result is associated with a
prediction score. This value positively correlates with an increase
in consistency of tumour types represented by the five-nearest
neighbours of a given test sample. Information about patient
gender and anatomical site of biopsy was provided. A prediction
score was given that comprises weightings for the site of biopsy,
gender and the five-nearest neighbour analysis.
Table 1 Patient characteristics
Age (years)
Median 65
Range 35–88
Gender
Male/female 10/11
Survival (months)
Median 4
Range 0.5 to 48+
Stage
PS 0 4
PS 1 7
PS 2 5
PS 3–4 5
Histology
Adenocarcinoma 6
Poorly differentiated adenocarcinoma 10
Undifferentiated carcinoma 2
Not available 3
Lymph nodes (N) 5
Mediastinal 1
Supraclavicular 1
Inguinal 3
Viscera (N) 15
Liver 5
Peritoneum 3
Pleura 2
Ascites 1
Testis 1
Skin 2
Ovary 1
No. of metastatic sites
11 8
23
420
PS¼performance status.
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A case-by-case analysis of the patients was performed. Key
outcomes were whether the GEM prediction was clinically feasible,
agreed with clinical characteristics and histology results and
whether the prediction would have changed management. A
survival analysis was performed on the population and a
prediction of survival based on median published survival time
following tumour-specific treatment (Coleman et al, 2004).
RESULTS
Patient characteristics
Patient characteristics are given in Table 1. The median age of
patients was 65 years, with 8 out of 21 patients below the age of 60
years. Generally, the clinical characteristics of the patients were
typical for a CUP population. Out of 21 patients, 5 were of poor PS
and unable to receive palliative treatment, but 11 out of 21 were of
PS 0–1 and 9 out of 21 proceeded to palliative chemotherapy, the
remainder being placed on surveillance. Out of 21 patients, 18 had
a single site of metastasis. Although the sample may be considered
unrepresentative because 18 patients had only one metastatic site,
the median survival of this patient cohort was 4 months, consistent
with a cohort of patients with a significant tumour load and a poor
prognosis. The short median survival was influenced by five
patients with poor PS not suitable for chemotherapy. The
overall survival is consistent with data from randomised
chemotherapy studies with median survival of 6–9 months
(Pavlidis et al, 2003).
Patients with CUP in well-described subgroups (see eligibility)
were excluded from our study, as they are often treated as for a
probable primary site: a high neck node with squamous cell
carcinoma histology is treated as a head and neck cancer despite a
normal nasopharyngoscopy, and an axillary node with adenocar-
cinoma histology is often treated as breast cancer despite a normal
breast. The survival of these subgroups is in most cases equivalent
to that of the adopted primary cancers.
Table 2 Results from diagnostic gene profiling: predicted site of origin, prediction score and five closest tumour types
Patient
Predicted
site of origin
Prediction
score
Nearest
neighbour 1
Nearest
neighbour 2
Nearest
neighbour 3
Nearest
neighbour 4
Nearest
neighbour 5
1 Small-cell-lung cancer 1 Small-cell-lung cancer Small-cell-lung cancer Small-cell-lung cancer Small-cell-lung cancer Small-cell-lung cancer
2 Adenocarcinoma of
the breast
0.40 Endometrial cancer Adenocarcinoma of
the breast
Adenocarcinoma of
the ovary
Adenocarcinoma of
the breast
Adenocarcinoma of
the ovary
3 Adenocarcinoma of
the breast
0.81 Adenocarcinoma of
the breast
Adenocarcinoma of
the breast
Adenocarcinoma of
the breast
Adenocarcinoma of
the breast
Adenocarcinoma of
the prostate
4 Adenocarcinoma of
the colon
0.80 Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the pancreas
Adenocarcinoma of
the pancreas
Adenocarcinoma of
the breast
5 Adenocarcinoma of
the colon
1 Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
6 Adenocarcinoma of
the colon
1 Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
7 Adenocarcinoma of
the colon
0.59 Adenocarcinoma of
the stomach
Adenocarcinoma of
the breast
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
8 Adenocarcinoma of
the small or large
bowel
1 Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
Adenocarcinoma of
the colon
9 Adenocarcinoma of
the small or large
bowel
0.81 Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Liver cancer Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
10 Adenocarcinoma of
the small or large
bowel
1 Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
11 Adenocarcinoma of
the small or large
bowel
1 Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the small or large
bowel
12 Adenocarcinoma of
the ovary
1 Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
13 Adenocarcinoma of
the ovary
0.21 Adenocarcinoma of
the ovary
Adenocarcinoma of
the pancreas
Adenocarcinoma of
the stomach
Adenocarcinoma of
the small or large
bowel
Bile duct and gall
bladder cancer
14 Adenocarcinoma of
the ovary
0.80 Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Endometrial cancer Adenocarcinoma of
the ovary
15 Adenocarcinoma of
the ovary
0.61 Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Adenocarcinoma of
the ovary
Endometrial cancer Adenocarcinoma of
the ovary
16 Mesothelioma 0.39 Adenocarcinoma of
the ovary
Adenocarcinoma of
the pancreas
Mesothelioma Mesothelioma Adenocarcinoma of
the stomach
17 Bladder cancer 1 Bladder cancer Bladder cancer Bladder cancer Bladder cancer Bladder cancer
18 Adenocarcinoma of
the endometrium
0.60 Adenocarcinoma of
the endometrium
Adenocarcinoma of
the ovary
Adenocarcinoma
endometrium
Adenocarcinoma
endometrium
Adenocarcinoma of
the ovary
19 Adenocarcinoma of
the pancreas
0.82 Adenocarcinoma of
the small or large
bowel
Adenocarcinoma of
the stomach
Adenocarcinoma of
the pancreas
Adenocarcinoma of
the pancreas
Adenocarcinoma of
the stomach
20 Cholangiocarcinoma 0.80 Cholangiocarcinoma Cholangiocarcinoma Cholangiocarcinoma Cholangiocarcinoma Adenocarcinoma of
the pancreas
21 Adenocarcinoma of
the stomach
0.4 Adenocarcinoma of
the stomach
Adenocarcinoma of
the stomach
Bile duct and gall
bladder cancer
Adenocarcinoma of
the ovary
Cervical squamous
cell carcinoma
Gene expression profiling in CUP
J Bridgewater et al
1427
British Journal of Cancer (2008) 98(8), 1425–1430 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDiagnosis and GEM results
Tumour origin predictions for samples in this study were obtained
from paraffin-fixed tissue biopsies. Gene expression data of each
sample were compared to the CupPrint database. Expression of
495 genes is quantified, and a prediction of tumour origin
generated using a k-nearest neighbour algorithm is applied.
In Table 2, the GEM-predicted diagnosis, prediction score and
five closest tumour types for each of the 21 patients of this study
are listed. The predicted diagnosis is the most likely site of origin.
The prediction score is an indication of the homogeneity in the top
five closest tumour types, for example, samples with a high
prediction score (40.8) have at least four of the top five closest
tumour types in common. The predicted site of origin is the tumour
in the database to which the samples have the most similarity to.
For 14 out of 21 patients, the predicted diagnosis suggested a
commonly occurring foster primary tumour (colon, breast and
ovary). For 7 out of 21 patients, the predicted site of origin
proposes a less common primary site. The historical median
survival for those patients with common tumours with tumour-
specific therapy would be expected to be greater than that
documented for this population (Hurwitz et al, 2004; Robert
et al, 2006).
In three patients, the clinical scenario was inconsistent with the
GEM-predicted foster primary (Table 3). For case 16, the predicted
site of origin was mesothelioma, which is an incorrect result, as
adenocarcinoma had been identified histologically. For case 18, the
predicted site of origin of endometrial carcinoma is unlikely, as the
patient had a normal hysterectomy specimen the previous year.
For case 19, the predicted site of origin of pancreatic adenocarci-
noma is also unlikely, as the positron emission tomography (PET)
and CT did not demonstrate a primary pancreatic site and the IHC
result was not supportive of a pancreatic primary. In addition, the
patient is alive and well 24 months after diagnosis, inconsistent
with the median survival for patients with metastatic adenocarci-
noma of the pancreas (6 months with chemotherapy; Burris et al,
1997).
Reproducibility
There was a consistency between identical samples analysed
independently. Three samples from case 3 submitted blind to the
laboratory as three different patients resulted in identical reports.
Analysis of two samples from different sites of tumour metastasis
in the same patient resulted in the identification of the same origin
as primary tumour, indicating accuracy and reproducibility of the
test. This also means that the site of metastasis, in this case lymph
node and skin, did not substantially affect the genomic profile of
this sample.
Table 3 Suggested management change for patients after GEM analysis and likely change in outcome
Patient
Working
diagnosis
Actual
treatment GEM result
Change of
treatment Change to
Actual
survival
Predicted
survival
Likely change
in outcome
1 Sarcoma ECF Small-cell-lung cancer Yes Carboplatin
Etoposide
89 N o
2 Unknown Supportive care Adenocarcinoma
of the breast
Yes Doxorubicin
Paclitaxel
7 24 Yes
3 Unknown Surveillance Adenocarcinoma
of the breast
Yes Surgery to breast 48+ 24 Yes
4 Bowel 5FU Adenocarcinoma of the
small or large bowel
Yes Oxaliplatin
Fluoropyrimidine+
9 24 Yes
5 Unknown Supportive care Adenocarcinoma of the
small or large bowel
No No 2 24 No
6 Unknown Supportive care Adenocarcinoma of the
small or large bowel
No No 1 24 No
7 Unknown ECF chemotherapy Adenocarcinoma of the
small or large bowel
Yes Oxaliplatin
Fluoropyrimidine+
7 24 Yes
8 Unknown Supportive care Adenocarcinoma of the
small or large bowel
Yes Oxaliplatin
Fluoropyrimidine+
1 24 Yes
9 Unknown Supportive care Adenocarcinoma of the
small or large bowel
No No change 1 24 No
10 Unknown Supportive care Adenocarcinoma of the
small or large bowel
No No change 8 24 No
11 Unknown Supportive care Adenocarcinoma of the
small or large bowel
Yes Oxaliplatin
Fluoropyrimidine+
7 24 Yes
12 Unknown Supportive care Epithelial ovarian cancer Yes Paclitaxel
Carboplatin
33+ 36 Yes
13 Ovarian cancer CF chemotherapy Epithelial ovarian cancer Yes Paclitaxel
Carboplatin
0.5 36 Yes
14 Unknown Cisplatin 5FU Epithelial ovarian cancer Yes Paclitaxel
Carboplatin
33 6
15 Ovarian cancer Carboplatin Epithelial ovarian cancer No No change 33+ 36 No
16 Bowel cancer CF chemotherapy Mesothelioma No NA 2 — —
17 Unknown Supportive care Bladder cancer Yes Bladder-specific
chemotherapy
0.5 14 Yes
18 Unknown Supportive care Endometrial cancer No NA 18+ 12 —
19 Supportive care Adenocarcinoma of
the pancreas
No
20 Lymphoma carcinoma CHOP cisplatin Cholangiocarcinoma Yes Cholangiocarcinoma-specific
chemotherapy
24 12 Yes
21 Unknown ECF Adenocarcinoma of
the stomach
Yes 3+ 12 Yes
CF¼cisplatin and fluorouracil; CHOP¼cyclophosphamide, doxorubicin, vincristine and prednisolone; ECF¼epirubicin, cisplatin and 5-fluorouracil; 5FU¼5-fluorouracil;
GEM¼gene expression microarray; NA¼not available.
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Potential changes in management are described. Twelve patients
(57%) may have had a change in management if GEM prediction
had been available at the time of diagnosis. For example, in patient
2, the clinical algorithm, including a negative mammogram and
oestrogen receptor-negative tumour tissue, did not reveal the
primary cancer (Table 3). However, if the diagnosis of breast
cancer as primary cancer would have been known earlier, the
patient could have been treated with breast cancer-specific
therapy.
For nine patients, supportive care was the primary management,
and improved diagnosis may not have led to management change
in all of these patients. The diagnostic profiling provided a feasible
clinical diagnosis yet a change of treatment would have been
unlikely to change outcome in patients with poor PS, as patients
with poor PS would be unlikely to receive and benefit from
chemotherapy. A prospective study would more accurately identify
the proportion of patients whose management would change
following a GEM prediction.
DISCUSSION
This study proposes the potential clinical use of an improved
diagnosis for CUP patients. The primary findings are that a
clinically feasible result was obtained in 18 out of 21 cases, that
foster primaries were mostly (14 out of 21) common cancers and
that the management would be influenced in 12 out of 21 cases.
Multiple chemotherapy empirical regimens have been used in
CUP without clear advantage. The a priori explanation lies in the
heterogeneity of tumours that may constitute a CUP patient
population and lack of specificity of any empirical combination.
Improved diagnosis and the use of specific regimen as for the
common tumour types is clearly desirable.
The current standard of care employs IHC as an adjunct to
conventional clinical and pathological investigations (Varadhachary
et al, 2004). Despite a growing panel of antibodies, the success rate
in identifying specific subgroups of CUP patients is only 20%
(Pavlidis et al, 2003), although the use of a diagnostic algorithm is
able to correctly identify the primary sites of known primaries in
88% (Dennis et al, 2005). Computed tomography scanning of
abdomen and pelvis is very well documented and results in
detection of a primary site in 30–35% of patients. With
increasingly accurate diagnostic tools such as PET, endoscopic
ultrasound and improved IHC, the likelihood of misdiagnosis is
small. Nevertheless, there remains a core of patients for whom the
primary is uncertain. Rades et al (2001) reported that PET allowed
detection of the primary site in 43% (18 out of 42 patients) of the
study population that included only localised CUP based on
conventional staging procedures. Dissemination was detected by
PET in 38%, and in 69%, the PET result influenced the selection of
the definitive treatment. However, the false-positive rate of PET is
approximately 20%, since this method is not specific for tumour
tissue. Additionally, very small tumours cannot be seen with PET
(for review, see Jerusalem et al, 2003).
Persistent investigation in search of the primary tumour is often
time consuming and expensive yet futile. The total cost of all
investigations for CUP patients was calculated to be between $4500
and 18000 per patient (Schapira and Jarrett, 1995). It is possible
that some of these costs could be reduced if molecular profiling
would be used in the diagnostic process.
We propose that GEM diagnosis be considered when the
primary clinical algorithm has failed to provide a diagnosis.
The results from the genomic profiling should be weighed
carefully with the clinical picture and discriminatory tools such
as IHC.
We have presented the predicted primary sites for a cohort of
patients with CUP using diagnostic profiling. The analysis suggests
that the primary site can be predicted in the majority of patients,
that this prediction is robust and that those cancers proposed are
mostly common cancers. The hypothesis that therapy based on
diagnostic GEM prediction provides a more targeted therapy with
a consequent improvement in survival remains to be tested in
future clinical studies.
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